Showing 3631-3640 of 5910 results for "".
- SemaThera Board Names Garth Cumberlidge as President & CEOhttps://modernod.com/news/semathera-board-names-garth-cumberlidge-as-president-ceo/2479705/SemaThera announced that its board of directors has appointed Garth Cumberlidge as President and Chief Executive Officer. Dr. Cumberlidge was also elected to the board of directors of SemaThera. He will lead the company’s development programs in diabetic macular edema and other degenerative retin
- Johnson & Johnson Vision to Showcase New Data and Interactive Experiences at 2018 AAOpthttps://modernod.com/news/johnson-johnson-vision-to-showcase-new-data-and-interactive-experiences-at-2018-aaopt/2479707/Johnson & Johnson Vision will highlight new data at the 2018 American Academy of Optometry Annual Meeting (Academy 2018), held November 7-10 in San Antonio, Texas. Two paper presentations highlighting visual performance of photochromic contact lenses were designated among the “Most Newsworthy
- Clerio Vision: First Noninvasive Laser Vision Correction Procedures Performedhttps://modernod.com/news/clerio-vision-first-noninvasive-laser-vision-correction-procedures-performed/2479743/Leveraging technology developed at the University of Rochester that was recently recognized with a Nobel Prize, Clerio Vision is commercializing LIRIC—a novel, noninvasive method to correct human vision. The core technology has been in development for more than 15 year
- Johnson & Johnson Vision Launches MyAcuvue Subscription Programhttps://modernod.com/news/johnson-johnson-vision-launches-myacuvue-subscription-program/2479759/Johnson & Johnson Vision announced the launch of its MyAcuvue Subscription Program, developed to provide contact lens wearers greater access and convenience when purchasing an annual supply of Acuvue Brand contact lenses through their eye care professional. “We continue to look for way
- Melt Pharmaceuticals Initiates Clinical Development Program for its Patented MK Melt Conscious Sedation Drug Candidatehttps://modernod.com/news/melt-pharmaceuticals-initiates-clinical-development-program-for-its-patented-mk-melt-conscious-sedation-drug-candidate/2479764/Melt Pharmaceuticals, a subsidiary of Imprimis Pharmaceuticals, announced that following the presentation of clinical data on the MKO Melt (midazolam/ketamine/ondansetron) from a 611-patient IRB approved prospective, controlled, randomized, three arm comparator study at the American Academy of Op
- CooperVision’s Best Practices Reveal Inaugural EYEdea Lab Findings at Vision Expo Westhttps://modernod.com/news/coopervisions-best-practices-reveal-inaugural-eyedea-lab-findings-at-vision-expo-west/2479796/A panel at the Global Contact Lens Forum at Vision Expo West presented findings from the inaugural CooperVision Best Practices EYEdea Lab. Designed to help eye care professionals (ECPs) improve patient experiences and remain competitive amidst disruptive consumer healthcare purchasing trends, the
- Novartis: New Analysis of Phase 3 Brolucizumab Data Reinforces Superior Reduction of Retinal Fluidhttps://modernod.com/news/novartis-new-analysis-of-phase-3-brolucizumab-data-reinforces-superior-reduction-of-retinal-fluid/2479846/Novartis announced a new data analysis showing that retinal fluid was detected less often in patients treated with brolucizumab (RTH258) 6 mg versus aflibercept over four visits between weeks 36 to 48[1]. Retinal fluid is a key marker of disease activity in neovascular age-related macular degener
- Neurolens Appoints Davis Corley Chief Executive Officerhttps://modernod.com/news/neurolens-appoints-davis-corley-chief-executive-officer/2479848/Neurolens announced that its board of directors has named Davis Corley chief executive officer (CEO). Mr. Corley was a co-founder of neurolens in 2012 and has served as president since 2014, a role that he will continue. “Since day one, Davis has led the dev
- Ellex 2RT Retinal Rejuvenation Effective for Select Cases of Intermediate AMDhttps://modernod.com/news/ellex-2rt-retinal-rejuvenation-effective-for-select-cases-of-intermediate-amd/2479852/Ellex Medical Lasers Limited announced the results of the Ellex 2RT Laser Intervention in Age-Related Macular Degeneration (LEAD) multicenter clinical trial. The results of the trial were published in Ophthalmology. According to researchers involved in the LEAD trial, Ellex’s 2RT
- Optos Launches Monaco Ultra-Widefield Retinal Imaging Systemhttps://modernod.com/news/optos-launches-monaco-ultra-widefield-retinal-imaging-system/2479855/Optos has launched Monaco, its latest ultra-widefield device to the European ophthalmic market. Monaco is the only ultra-widefield retinal imaging system with integrated Optical Coherence Tomography (OCT), according to Optos. It produces a 200° single-capture optomap image in less than hal